Literature DB >> 2837716

Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat.

D E Moulin1, G S Ling, G W Pasternak.   

Abstract

Clinically, patients often demonstrate incomplete cross-tolerance between opiate analgesics. Although dispositional and pharmacokinetic factors may be a factor, our results suggest that differences in selectivity of various opioids for those opioid receptor subtypes involved in analgesia, mu 1, kappa and delta, also play an important role. In binding studies, levorphanol potently labelled all 3 classes whereas morphine was relatively selective for mu sites. Levorphanol infusions yielded tolerance to both morphine and levorphanol while morphine infusions selectively produced tolerance to morphine. This unidirectional tolerance might be due to the selectivity of morphine for mu receptors compared to levorphanol's ability to interact more potently with other relevant receptor subtypes. These observations raise the possibility that the order in which different opioid analgesics are administered may be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837716     DOI: 10.1016/0304-3959(88)90095-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  13 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

2.  Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.

Authors:  Jin Xu; Zhigang Lu; Ankita Narayan; Valerie P Le Rouzic; Mingming Xu; Amanda Hunkele; Taylor G Brown; William F Hoefer; Grace C Rossi; Richard C Rice; Arlene Martínez-Rivera; Anjali M Rajadhyaksha; Luca Cartegni; Daniel L Bassoni; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

3.  Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Authors:  Susruta Majumdar; Steven Grinnell; Valerie Le Rouzic; Maxim Burgman; Lisa Polikar; Michael Ansonoff; John Pintar; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

Review 4.  Levorphanol: the forgotten opioid.

Authors:  Eric Prommer
Journal:  Support Care Cancer       Date:  2006-10-13       Impact factor: 3.603

Review 5.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene.

Authors:  Jin Xu; Mingming Xu; Yasmin L Hurd; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

7.  Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene.

Authors:  Jeffrey S Wieskopf; Ying-Xian Pan; Jaclyn Marcovitz; Alexander H Tuttle; Susruta Majumdar; John Pidakala; Gavril W Pasternak; Jeffrey S Mogil
Journal:  Pain       Date:  2014-08-02       Impact factor: 6.961

8.  Clonidine and dexmedetomidine produce antinociceptive synergy in mouse spinal cord.

Authors:  Carolyn A Fairbanks; Kelley F Kitto; H Oanh Nguyen; Laura S Stone; George L Wilcox
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

9.  Modulation between high- and low-frequency transcutaneous electric nerve stimulation delays the development of analgesic tolerance in arthritic rats.

Authors:  Josimari M Desantana; Valter J Santana-Filho; Kathleen A Sluka
Journal:  Arch Phys Med Rehabil       Date:  2008-04       Impact factor: 3.966

10.  Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.

Authors:  Steven G Grinnell; Susruta Majumdar; Ankita Narayan; Valerie Le Rouzic; Michael Ansonoff; John E Pintar; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2014-06-26       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.